The Khavinson bioregulator research programme has run continuously at the St Petersburg Institute of Bioregulation and Gerontology since the 1970s. It has produced a large body of peptide research covering short-peptide bioregulators derived from various tissue extracts, with the pineal-tissue-derived Epitalon (a tetrapeptide, Ala-Glu-Asp-Gly) receiving the most extensive characterisation and the strongest long-term follow-up work.

The programme's core hypothesis is that short-peptide bioregulators derived from specific tissues can modulate gene expression, telomerase activity, and downstream physiological function in ways that translate into measurable longevity and healthspan effects. Epitalon is the flagship compound for this hypothesis in the pineal-cognitive-ageing research angle.

The extended follow-up study enrolled elderly patients (typical age 60-75 at baseline) from the St Petersburg region and administered periodic courses of Epitalon (parenteral or oral) over the multi-year study period. The comparison arm received standard geriatric care without Epitalon.

The primary endpoint was all-cause mortality across the 10-year follow-up window. Secondary endpoints included cardiovascular mortality, cancer mortality, quality-of-life measures, and biomarkers of ageing including immune function, endocrine markers, and physical-function measures.

Treatment cycles followed the standard Khavinson bioregulator dosing pattern — 10-day courses repeated at 4-6 month intervals across the follow-up window, delivering cumulative exposure that the group's mechanism-of-action framework predicts as sufficient for the biological effects.

The published follow-up reports mortality reductions in the Epitalon arm relative to the standard-care comparison. Reported reductions include approximately 45-50% reduction in all-cause mortality and comparable reductions in cardiovascular and cancer-specific mortality subcategories over the 10-year follow-up window.

Secondary endpoint improvements included preserved immune function, preserved endocrine profiles (particularly melatonin-cortisol relationships), and preserved physical function relative to the standard-care comparison. Quality-of-life measures showed corresponding improvements.

Effect sizes are substantial — larger than typical for pharmaceutical longevity interventions in the mainstream literature — but the trial design and methodological limits (see below) mean these effect sizes should be interpreted with caution rather than as directly-comparable to modern RCT-derived effect estimates.

Several caveats are appropriate when weighing this evidence from a Western regulatory-science standpoint. The trial was not double-blind placebo-controlled — Russian clinical-trial methodology of the 1990s and early 2000s did not universally reach modern Western standards, and open-label longitudinal designs are subject to allocation bias, differential attrition, and outcome-assessment bias.

The trial was single-centre and single-programme — the results have not been independently replicated by Western regulatory-standard trial groups. The published reports are largely in Russian and have not been subjected to Western meta-analytic scrutiny.

Publication bias is plausible — the available reports are uniformly positive; if null follow-up cohorts exist, they would substantially change the pooled picture. And the effect-size magnitude is a warning sign — mortality reductions in this range are extraordinarily large by mainstream-medicine standards and should be treated with corresponding scepticism until independent replication is available.

The Khavinson Epitalon long-term follow-up is the strongest long-term human data on any short-peptide bioregulator, and provides a real basis for research interest in the compound's cognitive-ageing and longevity applications. It is, however, not strong enough on its own to support Western regulatory authorisation or to justify off-label clinical use outside Russia.

For research purposes the trial provides a credible clinical-context motivation for further mechanism and translational-model work on Epitalon and the wider Khavinson bioregulator family. For clinical purposes — outside Russia — Epitalon remains a research chemical, not an approved longevity intervention, and the trial body should be understood as supporting research interest rather than licensed clinical use.